BOSTON, Massachusetts, Oct. 19 [Category: BizHospital] -- The Dana-Farber Cancer Institute issued the following news release: * * * ADC Improves Outcomes for Patients with Advanced Triple-Negative Breast Cancer Who are Ineligible for Immune Checkpoint Inhibitors * Patients with an aggressive form of breast cancer who are not candidates for immune checkpoint inhibitor therapy showed significantly improved progression-free survival when treated with the antibody drug conjugate sacituzumab govi  more

WASHINGTON, Oct. 19 -- The Boston University School of Law's Program on Reproductive Justice, Immigrants' Rights and Human Trafficking Program and Racial Justice and Movement Lawyering Clinic, all of Massachusetts, have submitted a public comment letter to the U.S. Food and Drug Administration advocating for the expansion of access to mifepristone, which is a medication used in abortion procedures. The letter addresses FDA Citizen Petitions and urges the agency not to impose additional restricti  more

WASHINGTON, Oct. 20 -- The Identity Project (IDP), San Francisco, California, and Restore The Fourth (RT4), Belmont, Massachusetts, submitted a public comment letter to the U.S. Citizenship and Immigration Services (USCIS) expressing concerns regarding the agency's proposed collection of social media identifiers on immigration forms. The organizations argue that the initiative is not only unnecessary but also infringes on constitutional and human rights, highlighting possible violations of the P  more

BOSTON, Massachusetts, Oct. 18 [Category: BizHospital] -- The Dana-Farber Cancer Institute issued the following news release: * * * Novel Treatment Combination Improves Progression-Free Survival in Metastatic, Estrogen-Receptor-Positive HER-2-Negative Breast Cancer * Patients with estrogen-receptor-positive HER-2-negative advanced breast cancer showed significantly improved progression-free survival when treated with an oral combination regimen that includes giredestrant, a novel, next-gener  more